MedTrace Logo

A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza

NCT00705406 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 405

Last updated 2015-02-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether peramivir is safe and effective in the treatment of uncomplicated seasonal influenza.

Conditions

  • Acute, Uncomplicated Human Influenza

Interventions

DRUG

Peramivir

600 mg peramivir administered as bilateral 2-mL intramuscular injection

DRUG

Placebo

Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.

Sponsors & Collaborators

  • BioCryst Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-04-30
Completion
2009-10-31

Countries

  • United States
  • Australia
  • New Zealand
  • South Africa

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00705406 on ClinicalTrials.gov